+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
FEMALE
ID07779538

Randomized Phase IbIII Trial Comparing Trastuzumab Plus Bevacizumab Versus Bevacizumab as First-Line Maintenance Therapy in Epithelial Ovarian Cancer

Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2026-11-04

420

Participants Needed

3

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of trastuzumab and bevacizumab as a first-line maintenance treatment for women with epithelial ovarian cancer. This randomized, open-label, multicenter phase IbIII clinical trial is designed to assess safety, tolerability, and effectiveness of this combination compared to bevacizumab alone. Participants have stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer and have completed first-line platinum-based chemotherapy plus bevacizumab without disease progression. The trial has two phases Phase Ib focuses on safety and tolerability of SHR-A1811 trastuzumab combined with bevacizumab as maintenance therapy. Phase III compares efficacy and safety of the combination against bevacizumab alone as maintenance therapy. Participants receive assigned treatments following completion of first-line platinum-based chemotherapy plus bevacizumab. The study uses a randomized, parallel design to allocate participants into two groups. Participants undergo regular assessments including monitoring for dose-limiting toxicity within 21 days and progression-free survival over approximately 3 years with evaluations every 12 weeks initially, then every 24 weeks. Additional measures include adverse events, drug levels, antibody responses, overall survival, response rates, disease control, duration of response, time to progression, tumor marker response, and time to next treatment. Safety and efficacy data are collected throughout treatment and follow-up periods, lasting until study completion in 2030.

CONDITIONS

Brief Title

Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer

Research Team

S

Shuni Wang, M.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here